Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model

American Journal of Neurodegenerative Diseases

Volumn 6, Issue 2, 2017, Pages 15-25

  Garcia Esparcia, Paula ^a,b,c   Sideris Lampretsas, Georgios ^d   Hernandez Ortega, Karina ^a   Grau Rivera, Oriol ^e   Sklaviadis, Theodoros ^d   Gelpi, Ellen ^e   Ferrer, Isidro ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer s disease; APP PS1 transgenic mouse; Nucleolar chaperones; Protein synthesis; RRNAs; Transcription; Translation

Indexed keywords

AMYLOID BETA PROTEIN; ELONGATION FACTOR 1ALPHA; ELONGATION FACTOR 2; INITIATION FACTOR; INITIATION FACTOR 3 ETA; NUCLEOLIN; NUCLEOPHOSMIN; RIBOSOME PROTEIN; RNA 18S; RNA 28S; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UPSTREAM BINDING TRANSCRIPTION FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FRONTAL CORTEX; GEL ELECTROPHORESIS; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUSE; MOUSE MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; SOMATOSENSORY CORTEX; TRANSGENIC MOUSE; VERY ELDERLY; WESTERN BLOTTING;

EID: 85024108938     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. da Silva AM, Payão SL, Borsatto B, Bertolucci PH, Smith MA. Quantitative evaluation of rRNA in Alzheimer’s disease. Mech Ageing Dev 2000; 120: 57-64.
2. Dönmez-Altuntas H, Akalain H, Karaman Y, Demirtas H, Imamoglu N, Ozkul Y. Evaluation of the nucleolar organizer regions in Alzheimer’s disease. Gerontology 2005; 51: 297-301.
3. Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M. Epigenetic silencing of nucleolar rRNA genes in Alzheimer’s disease. PLoS One 2011; 6: e22585.
4. Sajdel-Sulkowska EM, Marotta CA. Alzheimer’s disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science 1984; 225: 947-949.
5. Shan X, Tashiro H, Lin CL. The identification and characterization of oxidized RNAs in Alzheimer’s disease. J Neurosci 2003; 23: 4913-4921.
6. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G. Neuronal RNA oxidation is a prominent feature of familial Alzheimer’s disease. Neurobiol Dis 2004; 17: 108-113.
7. Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, Perry G. Oxidative damage to RNA in neurodegenerative diseases. J Biomed Biotechnol 2006; 2006: 82323.
8. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tartakoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 2005; 280: 20978-20986.
9. Ding Q, Markesbery WR, Cecarini V, Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer’s disease. Neurochem Res 2006; 31: 705-710.
10. Shan X, Lin CL. Quantification of oxidized RNAs in Alzheimer’s disease. Neurobiol Aging 2006; 27: 657-662.
11. Langstrom NS, Anderson JP, Lindroos HG, Winblad B, Wallace WC. Alzheimer’s disease-associated reduction of polysomal mRNA translation. Brain Res Mol Brain Res 1989; 5: 259-269.
12. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer’s disease and Creutzfeldt-Jakob’s disease. Neuropathol Appl Neurobiol 2002; 28: 441-451.
13. Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport 2004; 15: 2237-2240.
14. Ding Q, Markesbery WR, Chen Q, Li F, N. Keller JN. Ribosome dysfunction is an early event in Alzheimer’s disease. J Neurosci 2005; 25: 9171-9175.
15. Hernández-Ortega K, Garcia-Esparcia P, Gil L, Lucas JJ, Ferrer I. Altered machinery of protein synthesis in Alzheimer’s: from the nucleolus to the ribosome. Brain Pathol 2016; 26: 593-605.
16. Grau-Rivera O, Gelpi E, Nos C, Gaig C, Ferrer I, Saiz A, Lladó A, Molinuevo JL, Graus F, Sánchez-Valle R; Neurological Tissue Bank Collaborative Group. Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis 2015; 15: 350-360.
17. Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M. Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 2008; 9: 181-194.
18. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
19. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 12: 389-404.
20. Thal DR, Rüb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.
21. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer’s Association. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
22. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17: 1005-1013.
23. Aso E, Lomoio S, López-González I, Joda L, Carmona M, Fernández-Yagüe N, Moreno J, Juvés S, Pujol A, Pamplona R, Portero-Otin M, Martín V, Díaz M, Ferrer I. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer’s disease. Brain Pathol 2012; 22: 636-653.
24. Barrachina M, Castaño E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006; 49: 276-284.
25. Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN, Bonnert TP, Ferrer I, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, Grünblatt E, Palkovits M, Parchi P, Capellari S, Arzberger T, Kretzschmar H, Roncaroli F, Dexter DT, Reynolds R. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe study. Acta Neuropathol 2012; 124: 893-903.